Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at

Upcoming Events

May 5, 2016
8:30 AM
Webcast Regeneron Pharmaceuticals Q1 2016 Earnings Conference Call
May 10, 2016
8:00 AM PT
Webcast Bank of America Merrill Lynch Healthcare Conference
May 19, 2016
11:00 AM ET
Webcast Barclays 2016 Biopharmaceuticals CEO/CFO Conference Call Series
Jun 10, 2016
10:30 AM ET
2016 Annual Meeting of Shareholders

View all releases Recent Press Releases

Apr 29, 2016 Regeneron Announces Upcoming 2016 Investor Conference Presentations
Apr 15, 2016 Regeneron to Report First Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on May 5, 2016
Apr 13, 2016 Regeneron Hires Sally A. Paull as Senior Vice President, Human Resources
Apr 11, 2016 Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics
Apr 5, 2016 Regeneron and MedImmune Enter into Licensing Agreement for the Development of Antibody Drug Conjugates to Treat Cancer
Apr 1, 2016 Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Mar 30, 2016 Regeneron and Sanofi to Present Phase 3 Praluent® (alirocumab) Injection Clinical Trial Data at ACC.16
Mar 24, 2016 Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases
Mar 23, 2016 Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy
Mar 16, 2016 Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal

Form content here please :)